Patritumab deruxtecan in HER2-negative breast cancer: part B results of the window-of-opportunity SOLTI-1805 TOT-HER3 trial and biological determinants of early response
Brasó-Maristany, Fara, Ferrero-Cafiero, Juan Manuel, Falato, Claudette, Martínez-Sáez, Olga, Cejalvo, Juan Miguel, Margelí, Mireia, Tolosa, Pablo, Salvador-Bofill, Francisco Javier, Cruz, Josefina, González-Farré, Blanca, Sanfeliu, Esther, Òdena, Andreu, Serra, Violeta, Pardo, Francisco, Luna Barrera, Ana María, Arumi, Miriam, Guerra, Juan Antonio, Villacampa, Guillermo, Sánchez-Bayona, Rodrigo, Ciruelos, Eva, Espinosa-Bravo, Martín, Izarzugaza, Yann, Galván, Patricia, Matito, Judith, Pernas, Sonia, Vidal, Maria, Santhanagopal, Anu, Sellami, Dalila, Esker, Stephen, Fan, Pang-Dian, Suto, Fumitaka, Vivancos, Ana, Pascual, Tomás, Prat, Aleix, Oliveira, Mafalda
Published in Nature communications (11.07.2024)
Published in Nature communications (11.07.2024)
Get full text
Journal Article